Search

Mecobalamin

Ranibizumab

In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for

Gemcitabine

It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. … [L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.

Letermovir

Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. … [A31290] Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis.[L1021]

Insulin glulisine

Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening

Terlipressin

[A2601] It is a prodrug of [lypressin], or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. … [A252672] The drug was first approved by the FDA in September 2022.[L43217]

Lonoctocog alfa

Antihemophilic factor (recombinant), PEGylated

PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529]. … Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].

Gemtuzumab ozogamicin

On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered

Capsaicin

Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. … The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.